

22 July 2016

## Letter from the Chairman

To the shareholders of Optiscan:

### 2 for 9 Rights Issue to Existing Shareholders

Optiscan Imaging Limited is delighted to confirm the lodgement of the short form prospectus for our existing shareholders.

The non-renounceable pro-rata Rights Issue of 2 new shares for every 9 Shares is at an issue price of 2.5 cents (\$0.025) per new share issued. The Rights Issue is fully underwritten and will raise approximately \$1.4 million through the issuance of 56.6 million shares.

The recent placement by sophisticated shareholders (\$0.75m), the recently announced director loan conversion (\$0.6m) and the Rights Issue now totals \$2.75m raised to support the future direction of the company.

As outlined in the prospectus, all funds received will be used to actively drive the strategic direction of the Optiscan business including, but not limited to, the following:

- Driving the commercialisation of the CellLIVE product
- Development and commercialisation of the 2.4mm probe
- Development and commercialisation of the 2<sup>nd</sup> generation rigid system
- Completion and launch of the Carl Zeiss collaboration project
- General working capital and administrative costs (including the costs associated with the Rights Issue)

The Rights Issue is the latest building block in the restructure and redevelopment of Optiscan that has included the new board (announced on 3 May 2016) and the appointment of Archie Fraser as CEO (announced on 13 May 2016).

The capital raising will enable Optiscan to deliver its new mission which I shared with you when the new Board was appointed:

“To create shareholder wealth through the profitable delivery of microscopic imaging and related technologies into the global market.”

Optiscan’s patented technology opens up a wealth of commercial opportunities around the world and the Board is confident that we now have the right people and structures in place to capitalise on the opportunities in front of us and deliver shareholder wealth.

Kind regards,

Alan Hoffman  
Chairman